title: Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial design.
abstract: BACKGROUND
  The mechanism underlying rapid, statin-induced event reduction in patients with an acute coronary syndrome (ACS) remains to be clarified.
  
  
  OBJECTIVE
  The primary objective is to compare the efficacy of rosuvastatin 20 mg/day and atorvastatin 80 mg/day in reducing the apolipoprotein B/apolipoprotein A-1 (apoB/apoA-1) ratio at three months, in ACS patients. Secondary objectives include a comparison of the effects of early-started rosuvastatin and placebo on inflammatory markers.
  
  
  METHODS
  This is a randomized, double-blind, parallel-group study. Patients with non-ST-segment elevation ACS, symptom onset less than 48 h before admission, and for whom a percutaneous coronary intervention is planned, are eligible for inclusion and are randomized into three groups (G1, G2 and G3). The study comprises two double-blind periods. Period 1 starts at hospital admission and lasts until Day 0 (discharge or less or equal to 6 days after admission); patients in G1 receive one tablet of rosuvastatin 20 mg/day and patients in G2 and G3 receive one matching placebo tablet per day. Period 2 starts at Day 0 and lasts for three months; patients in G1 continue to receive rosuvastatin 20 mg/day, patients in G2 receive rosuvastatin 20 mg/day and patients in G3 receive atorvastatin 80 mg/day. Recruitment of 1075 patients will ensure an 80 power to detect a 3% difference in percentage change in the apoB/apoA-1 ratio and a 20% difference in percentage change in high-sensitivity C-reactive protein.
  
  
  RESULTS
  Inclusion phase is complete; results will be reported at a later date.
  
  
  CONCLUSIONS
  This is the first trial investigating the effect of statins on apolipoproteins in ACS patients.
authors.affiliation: Hôpital cardiologique, CHRU de Lille, Lille, France.
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Lablanche
authors.forename: Nicolas
authors.initials: N
authors.lastname: Danchin
authors.forename: Michel
authors.initials: M
authors.lastname: Farnier
authors.forename: Alain
authors.initials: A
authors.lastname: Tedgui
authors.forename: Eric
authors.initials: E
authors.lastname: Vicaut
authors.forename: Joaquim
authors.initials: J
authors.lastname: Alonso
authors.forename: Peter
authors.initials: P
authors.lastname: Crean
authors.forename: Attilio
authors.initials: A
authors.lastname: Leone
authors.forename: Joa
authors.initials: J
authors.lastname: Morais
authors.forename: Massimo
authors.initials: M
authors.lastname: Santini
authors.forename: Muriel
authors.initials: M
authors.lastname: Licour
authors.forename: Mohamed
authors.initials: M
authors.lastname: Farah
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Tardif
mesh_terms: D054058:Acute Coronary Syndrome / Q000097:blood / Q000188:drug therapy*; D000293:Adolescent; D000328:Adult; D016632:Apolipoprotein A-I / Q000097:blood* / Q000187:drug effects; D001055:Apolipoproteins B / Q000097:blood* / Q000187:drug effects; D000069059:Atorvastatin; D004311:Double-Blind Method; D005464:Fluorobenzenes / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011758:Pyrroles / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D005464:Fluorobenzenes; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D000069059:Atorvastatin